A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials
NCT07683897 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-07-30
Summary
This is an open label, multi-center, long-term safety and efficacy follow-up trial for participants who have been treated with Senza5 CART5.
Conditions
- Participants Treated With Senza5
Interventions
- BIOLOGICAL
-
Senza5 CART5
Senza5 CART5
Sponsors & Collaborators
-
Vittoria Biotherapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-31
- Primary Completion
- 2041-07-31
- Completion
- 2041-07-31
- FDA Drug
- Yes
More Related Trials
-
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
NCT03635632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
NCT01735604 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
NCT07259889 ·Status: RECRUITING ·Phase: PHASE1
-
First Study of the Safety of CNTO 888 in Patients With Solid Tumors
NCT00537368 ·Status: COMPLETED ·Phase: PHASE1
-
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
NCT01141491 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
NCT01061840 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
NCT05435339 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
NCT02929862 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Treating Patients With Kidney Cancer
NCT00014131 ·Status: TERMINATED ·Phase: PHASE1
-
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
NCT04137536 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
NCT01826877 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Personalized Neoantigen Cancer Vaccines
NCT03794128 ·Status: COMPLETED
-
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
NCT00050323 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05039931 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
NCT03295942 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
NCT00096941 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of 68Ga-R8760
NCT05999292 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
NCT04025216 ·Status: TERMINATED ·Phase: PHASE1
-
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
NCT05880043 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
NCT05076591 ·Status: SUSPENDED ·Phase: PHASE1
-
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03289962 ·Status: COMPLETED ·Phase: PHASE1
-
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
NCT06633341 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
NCT02509585 ·Status: TERMINATED ·Phase: PHASE2
-
Blood and Tissue Study of Patients in NIH Protocol 08-C-0800
NCT00923325 ·Status: COMPLETED